Veradermics, Inc.(MANE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MANE Veradermics, Inc.

休市中 07-24 16:00:00 EDT

109.51

-6.35

-5.48%

盘后109.51

+0.000.00%

19:34 EDT

最高117.93	最低109.27	成交量53.32万
今开115.40	昨收115.86	日振幅7.47%
总市值45.75亿	流通市值25.66亿	总股本4,178万
成交额6,011万	换手率2.28%	流通股本2,343万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MANE","market":"US","secType":"STK","nameCN":"Veradermics, Inc.","latestPrice":109.51,"timestamp":1784923200000,"preClose":115.86,"halted":0,"volume":533173,"hourTrading":{"tag":"盘后","latestPrice":109.51,"preClose":109.51,"latestTime":"19:34 EDT","volume":2218,"amount":243151.86,"timestamp":1784936050288,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0548075263248748,"floatShares":23429586,"shares":41778687,"eps":-2.0303893,"marketStatus":"休市中","change":-6.35,"latestTime":"07-24 16:00:00 EDT","open":115.4,"high":117.93,"low":109.27,"amount":60107977.93855,"amplitude":0.074745,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.0303893,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"listingDate":1770181200000,"exchange":"NYSE","adjPreClose":115.86,"preHourTrading":{"tag":"盘前","latestPrice":116,"preClose":115.86,"latestTime":"09:22 EDT","volume":403,"amount":46546.699888,"timestamp":1784899328167,"change":0.14,"changeRate":0.001208,"amplitude":0.017176},"postHourTrading":{"tag":"盘后","latestPrice":109.51,"preClose":109.51,"latestTime":"19:34 EDT","volume":2218,"amount":243151.86,"timestamp":1784936050288,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9598647480958211,"impliedVol":0.9828,"impliedVolPercentile":0.875},"requestUrl":"/m/hq/s/MANE","defaultTab":"news","newsList":[{"id":"2651465277","title":"Veradermics女性脱发新药Ⅱ期临床取得积极成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2651465277","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651465277?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:04","pubTimestamp":1784120640,"startTime":"0","endTime":"0","summary":"Veradermics公司公布了其口服药物VDPHL01治疗女性轻中度脱发的Ⅱ期临床试验积极结果。　　Study 207是一项开放标签Ⅱ期临床试验，共纳入28名成年女性受试者，分别接受VDPHL01 4.5mg每日一次或每日两次给药，持续6个月。　　VDPHL01是一种新型口服缓释米诺地尔制剂，目前正同步开展男性和女性雄激素性脱发的注册临床试验。Veradermics于7月15日上午召开了投资者电话会议，讨论Study 207的详细结果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-15/doc-inihxaeu7874849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135661380","title":"Veradermics旗下Vdphl01展现良好安全性，无治疗相关严重不良事件或心脏不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1135661380","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135661380?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:07","pubTimestamp":1784113624,"startTime":"0","endTime":"0","summary":"Veradermics公司宣布，其候选药物Vdphl01在一项研究中展现出良好的安全性特征。研究数据显示，该药物未引发任何与治疗相关的严重不良事件，亦未观察到心脏不良事件。这一结果初步验证了该疗法的安全性，为其后续临床开发提供了支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146038381","title":"Veradermics口服药物Vdphl01在女性型脱发治疗中取得积极“207”二期临床结果，为即将揭晓的“306”二/三期研究数据铺路","url":"https://stock-news.laohu8.com/highlight/detail?id=1146038381","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146038381?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:02","pubTimestamp":1784113323,"startTime":"0","endTime":"0","summary":"Veradermics, Inc. 旗下口服药物Vdphl01在针对女性型脱发的二期临床研究“207”中取得了令人鼓舞的成果。这一积极数据的公布，恰逢其更为关键的后续二/三期研究“306”的数据读出来临前夕，为公司在脱发治疗领域的进展增添了重要砝码。研究“207”的正面结果不仅验证了Vdphl01在目标患者群体中的潜力，也为即将到来的“306”研究数据解读奠定了乐观预期。投资者与行业观察者正密切关注这一系列临床数据的连贯性，以期评估Vdphl01最终商业化的前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111006527","title":"截至2026年3月31日，Veradermics公司现金、现金等价物及有价证券总额达3.908亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111006527","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111006527?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:50","pubTimestamp":1778586624,"startTime":"0","endTime":"0","summary":"截至2026年3月31日，Veradermics公司持有的现金、现金等价物及可流通证券总额达到3.908亿美元。这一财务数据反映了公司在报告期末的流动性资产状况，为评估其短期财务实力和运营灵活性提供了关键指标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127742505","title":"Veradermics Inc宣布VDPHL01临床试验达成所有主要及关键次要终点，统计学意义显著","url":"https://stock-news.laohu8.com/highlight/detail?id=1127742505","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127742505?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:04","pubTimestamp":1777287886,"startTime":"0","endTime":"0","summary":"Veradermics Inc最新公布的临床研究数据显示，其核心候选药物VDPHL01在关键试验中表现卓越，成功达成了预设的所有主要疗效终点及关键次要疗效终点。\n尤为值得注意的是，该药物在各项终点指标上均展现出高度显著的统计学差异，这一突破性进展为后续的监管审批和商业化进程奠定了坚实基础。试验结果的优异表现，预示着该疗法在目标治疗领域具有巨大的市场潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185394589","title":"Veradermics口服药物Vdphl01在雄性激素性脱发2/3期临床试验中实现早期、持续且显著的毛发生长效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1185394589","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185394589?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:02","pubTimestamp":1777287777,"startTime":"0","endTime":"0","summary":"Veradermics公司宣布，其研发的口服药物Vdphl01在针对雄性激素性脱发的积极2/3期“302”临床试验中，取得了令人鼓舞的成果。数据显示，该疗法能够促进早期、持续且强劲的毛发生长。\n这项临床试验结果标志着脱发治疗领域的重要进展。Vdphl01展现出的早期生效特性与持续改善效果，为受雄性激素性脱发困扰的患者提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189528976","title":"Veradermics将召开电话会议 讨论Vdphl01治疗男性轻中度雄激素性脱发II/III期‘302’研究顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1189528976","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189528976?lang=zh_cn&edition=full","pubTime":"2026-04-27 04:01","pubTimestamp":1777233676,"startTime":"0","endTime":"0","summary":"Veradermics公司宣布，将举行一场电话会议，专门讨论其候选药物Vdphl01用于治疗男性轻中度雄激素性脱发的II/III期‘302’临床试验所获得的顶线结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609514045","title":"防脱发企业VeraDermics上市：市值13亿美元 9个月亏4815万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609514045","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609514045?lang=zh_cn&edition=full","pubTime":"2026-02-07 06:10","pubTimestamp":1770415817,"startTime":"0","endTime":"0","summary":"专注于皮肤病领域的生物制药公司VeraDermics(NYSE:MANE)日前在美股上市，发行价为17美元，发行1508万股，募资总额为2.56亿美元。截至今日收盘，VeraDermics股价为37.16美元，市值为13亿美元。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260207/6390604141325207394345179.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260207/6390604141325207394345179.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n32603/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609634894","title":"植发药物开发商Veradermics(MANE.US)IPO定价17美元/股 上市首日暴涨122%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609634894","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609634894?lang=zh_cn&edition=full","pubTime":"2026-02-05 09:18","pubTimestamp":1770254331,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，植发药物开发商Veradermics上市首日收涨逾122%，报37.75美元，远高于其首次公开募股的发行价17美元。该公司在IPO中筹集了2.563亿美元。知情人士称，此次扩大发行规模后的IPO获得了数倍于发行量的超额认购。根据申报文件，Wellington Management曾表示有意按照IPO价格认购最多3000万美元的股份。据悉，Veradermics正在研发一种适用于男女性雄激素性脱发的口服非激素疗法。数据显示，Veradermics 在截至去年9月30日的九个月内净亏损为4810万美元，而上年同期的净亏损为2080万美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"植发药物开发商Veradermics(MANE.US)IPO定价17美元/股 上市首日暴涨122%","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174794357","title":"Veradermics Inc. 上调首次公开募股规模，以每股17.00美元定价发行1500万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1174794357","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174794357?lang=zh_cn&edition=full","pubTime":"2026-02-04 10:58","pubTimestamp":1770173894,"startTime":"0","endTime":"0","summary":"Veradermics Inc. 宣布，其首次公开募股（IPO）的最终定价为每股17.00美元。此次发行规模已上调至1500万股普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111688428","title":"礼来公司表示有意以IPO价格收购Veradermics最多4.9%流通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1111688428","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111688428?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:18","pubTimestamp":1770117533,"startTime":"0","endTime":"0","summary":"生物科技公司Veradermics, Inc.近日披露，全球制药巨头礼来公司已表明投资意向，计划在公司完成首次公开募股后，以发行价购入不超过总股本4.9%的普通股。这一战略投资若最终落地，将显著强化两家公司在皮肤病治疗领域的协同效应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU0823434583.USD","LU2089284900.SGD","LU1280957306.USD","LU2361044865.SGD","LU2168563687.JPY","IE00B7KXQ091.USD","IE0004445015.USD","LU0354030438.USD","IE00BKDWB100.SGD","LU1127390331.HKD","SG9999017495.SGD","LU0689472784.USD","LU2471134952.CNY","LU0096364046.USD","IE00BJJMRX11.SGD","LU1814569148.SGD","LU1989771016.USD","LU1291159041.SGD","BK4581","LU2552382058.USD","LU0234572021.USD","LU0079474960.USD","SGXZ81514606.USD","IE00B775H168.HKD","SG9999014880.SGD","SGXZ31699556.SGD","LU0256863902.USD","LU2211815571.USD","LU2360106947.USD","LU0158827781.USD","SG9999001176.SGD","LU1917777945.USD","LU1551013425.SGD","SGXZ99366536.SGD","LU0466842654.USD","LU0672654240.SGD","LU2491050154.USD","LU1623119135.USD","LU1720051017.SGD","LU2089984988.USD","SGXZ57979304.SGD","IE00BJT1NW94.SGD","IE00BN29S564.USD","LU2602419157.SGD","IE00BJJMRZ35.SGD","LU1974910355.USD","SG9999015945.SGD","SGXZ51526630.SGD","LU0889565916.HKD","LU2168564222.USD","LU0417517546.SGD","SG9999014906.USD","LU0203201768.USD","LU0708995401.HKD","LU1035775433.USD","LU0203202063.USD","LU2237443465.HKD","LU2237443978.SGD","LU2491050071.SGD","IE00B1XK9C88.USD","IE00BFSS7M15.SGD","LU2108987350.USD","LU0323591593.USD","LU0094547139.USD","LU1804176565.USD","IE00BK4W5M84.HKD","IE0005OL40V9.USD","SG9999014898.SGD","LU1064131342.USD","LU0471298777.SGD","IE00BK4W5L77.USD","LU0385154629.USD","LU0061475181.USD","SG9999015978.USD","LU2168564495.EUR","LU0238689110.USD","LU1232071149.USD","LU1868836914.USD","LU2746668974.SGD","LU0198837287.USD","LU0106261372.USD","LU2112291526.USD","LU0109391861.USD","LU0823416689.USD","IE00BJLML261.HKD","LU0471298694.HKD","LU2023251221.USD","LU0225283273.USD","LU2168564065.EUR","MANE","BK4599","LU1093756168.USD","IE00B4R5TH58.HKD","LU0820561818.USD","IE00BWXC8680.SGD","LU0882574055.USD","SG9999013999.USD","LU0354030511.USD","LU0823434740.USD","IE0004445239.USD","LU0432979614.USD","LU2746668461.USD","SG9999015952.SGD","LU0058720904.USD","BK4533","IE00B4JS1V06.HKD","LU0158827948.USD","LU1712237335.SGD","LU0353189763.USD","LU2896262040.SGD","LU2456880835.USD","IE00BKPKM429.USD","LU2265009873.SGD","LU0882574139.USD","LU0353189680.USD","LU0320765059.SGD","IE00B1BXHZ80.USD","IE00BFSS8Q28.SGD","LU2417539215.USD","LU1868836757.USD","LU0943347566.SGD","LU0640476718.USD","LU1551013342.USD","LU1868836591.USD","SG9999001176.USD","LU2237443622.USD","SG9999018857.SGD","LU2106854487.HKD","LU2552382132.HKD","LU2023250504.SGD","LU2271345857.HKD","LU1868837136.USD","LU2028103732.USD","LU2237443549.SGD","LU2471134523.USD","LU2111349929.HKD","LU1093756325.SGD","LU2361044949.HKD","IE00BJJMRY28.SGD","LU0122379950.USD","BK4588","LU2089283258.USD","LU2168564149.EUR","LU2552382215.SGD","SG9999018865.SGD","LU2357305700.SGD","LU2236285917.USD","LU2471134879.HKD","LU0210536198.USD","LU2471134796.USD","SG9999015986.USD","LU1868837300.USD","LU0787776722.HKD","LU1069344957.HKD","LU2264538146.SGD","SG9999014914.USD","BK4585","LU0097036916.USD","LU1267930730.SGD","LU1983299246.USD","LU2750360997.AUD","LU1548497426.USD","LU1023059063.AUD","LU2237443895.HKD","LU0316494557.USD","LU2237443382.USD","LU2461242641.AUD","LU2087625088.SGD","LLY","LU0786609619.USD","LU0006306889.USD","LU1366192091.USD","BK4516","LU0266013472.USD","LU2063271972.USD","LU0289739699.SGD","LU2237438978.USD","IE00B2B36J28.USD","LU0320765992.SGD","LU1720051108.HKD","LU1988902786.USD","LU2750360641.GBP","LU0109394709.USD","LU2324357040.USD","LU2468319806.SGD","LU2462157665.USD","LU0683600562.USD","LU0456855351.SGD","BK4007","LU1061106388.HKD","BK4534","LU0820561909.HKD","LU2361045086.USD","IE00BFTCPJ56.SGD","LU0114720955.EUR","GB00BDT5M118.USD","LU2491049909.HKD","LU0256863811.USD","LU1057294990.SGD","IE0009355771.USD","LU1323610961.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197029226","title":"礼来收购Veradermics普通股将不受承销商锁定期协议约束","url":"https://stock-news.laohu8.com/highlight/detail?id=1197029226","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197029226?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:18","pubTimestamp":1770117529,"startTime":"0","endTime":"0","summary":"根据最新披露的协议条款，Veradermics公司（Veradermics, Inc.）与礼来公司（Eli Lilly）达成的普通股收购交易出现重大突破——这些拟被收购的股份将完全豁免于承销商设置的锁定期协议限制。这意味着礼来在完成收购后即可自由处置所持股份，无需遵守常规IPO后禁止抛售的约束性条款。该安排显著区别于常规股权投资模式，反映出交易双方对股权流动性的特殊考量，可能为后续战略合作奠定灵活基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0158827781.USD","LU0320765059.SGD","LU1061106388.HKD","LU1093756325.SGD","LU2271345857.HKD","SGXZ81514606.USD","IE00BN29S564.USD","LU1868837136.USD","LU0354030511.USD","LU0114720955.EUR","LU2112291526.USD","LU2168564149.EUR","IE00B7KXQ091.USD","LU0256863902.USD","LU2087625088.SGD","SG9999015978.USD","LU1023059063.AUD","IE0005OL40V9.USD","IE00B2B36J28.USD","LU1267930730.SGD","LU0203201768.USD","LU1712237335.SGD","LU2552382058.USD","SG9999015945.SGD","LU2750360641.GBP","LU0079474960.USD","SG9999014880.SGD","LU0417517546.SGD","LU0943347566.SGD","IE00BJJMRY28.SGD","LU2360106947.USD","SGXZ57979304.SGD","LU0683600562.USD","LU0882574139.USD","LU0096364046.USD","LU2602419157.SGD","LU0432979614.USD","LU2471134952.CNY","LU2491050154.USD","LU0353189680.USD","LU2237443978.SGD","SG9999014906.USD","LU2111349929.HKD","LU0289739699.SGD","LU1868837300.USD","LU2491050071.SGD","IE00B4JS1V06.HKD","BK4585","SG9999015986.USD","LU2471134796.USD","IE00B1XK9C88.USD","LU2361044949.HKD","LU1093756168.USD","LU1232071149.USD","LU2168564222.USD","LU0320765992.SGD","LU2168564495.EUR","LU0466842654.USD","LU0198837287.USD","LU0820561818.USD","SGXZ99366536.SGD","LU2108987350.USD","LU2237438978.USD","LU0456855351.SGD","LU2417539215.USD","LU2023250504.SGD","LU0385154629.USD","LU1280957306.USD","LU2211815571.USD","SG9999014914.USD","LU0708995401.HKD","LU0471298777.SGD","SG9999014898.SGD","IE00BK4W5L77.USD","LU2063271972.USD","IE00B4R5TH58.HKD","LU0640476718.USD","LU1989771016.USD","BK4599","LU0203202063.USD","LU1983299246.USD","LU0109394709.USD","IE00BJT1NW94.SGD","LU1551013342.USD","LU2324357040.USD","IE00BFSS8Q28.SGD","LU1720051017.SGD","LU0256863811.USD","IE0004445239.USD","LU0006306889.USD","LU1720051108.HKD","LU1548497426.USD","LU2023251221.USD","LU2746668974.SGD","BK4007","LU2552382215.SGD","LU0210536198.USD","LU0122379950.USD","LU1366192091.USD","LU1868836591.USD","IE0004445015.USD","LU2237443549.SGD","LU2471134879.HKD","LU2552382132.HKD","IE00BK4W5M84.HKD","SGXZ51526630.SGD","IE0009355771.USD","LU1917777945.USD","LU0266013472.USD","LU0225283273.USD","LU1551013425.SGD","LU0471298694.HKD","LU2468319806.SGD","IE00BKPKM429.USD","LU0234572021.USD","BK4588","LU2237443622.USD","LU2491049909.HKD","SG9999017495.SGD","LU1974910355.USD","LU2750360997.AUD","LU0094547139.USD","LU2237443382.USD","SG9999001176.SGD","LU1814569148.SGD","LU1064131342.USD","LU0672654240.SGD","LU2237443465.HKD","LU0061475181.USD","SG9999018865.SGD","LU0323591593.USD","LU0106261372.USD","IE00BFSS7M15.SGD","LU2168563687.JPY","LU0882574055.USD","LU2456880835.USD","IE00BJJMRZ35.SGD","BK4516","LU0820561909.HKD","LU2237443895.HKD","LU0889565916.HKD","LU2461242641.AUD","GB00BDT5M118.USD","IE00BFTCPJ56.SGD","SG9999013999.USD","LU2106854487.HKD","LU1988902786.USD","BK4581","LU2746668461.USD","LU2361044865.SGD","LU2028103732.USD","LU0787776722.HKD","LU2264538146.SGD","SG9999001176.USD","LU1035775433.USD","IE00B1BXHZ80.USD","LU2089283258.USD","LU2896262040.SGD","LU1868836757.USD","LU0109391861.USD","LU0058720904.USD","BK4533","LU0238689110.USD","LU1069344957.HKD","LU0158827948.USD","LU0689472784.USD","MANE","SG9999018857.SGD","IE00BJLML261.HKD","LU0786609619.USD","IE00B775H168.HKD","LU0353189763.USD","IE00BKDWB100.SGD","LU2471134523.USD","LU2361045086.USD","LU0354030438.USD","IE00BWXC8680.SGD","LU0823416689.USD","LU0823434583.USD","LU2089284900.SGD","LU2089984988.USD","SG9999015952.SGD","LU2236285917.USD","IE0002141913.USD","LU1291159041.SGD","LU2462157665.USD","LU2265009873.SGD","LU1868836914.USD","LU1057294990.SGD","IE00BJJMRX11.SGD","LU1623119135.USD","SGXZ31699556.SGD","BK4534","LU0823434740.USD","LU2357305700.SGD","LU0097036916.USD","LU0316494557.USD","LU1804176565.USD","LU1127390331.HKD","LU1323610961.USD","LU2168564065.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607777957","title":"“秃头经济”新玩家：生发药企Veradermics(MANE.US)拟IPO募资2.14亿美元，市值冲刺5.34亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2607777957","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607777957?lang=zh_cn&edition=full","pubTime":"2026-01-29 11:30","pubTimestamp":1769657450,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，致力于毛发修复的生物制药公司 Veradermics Inc. 正寻求通过 IPO 筹集高达 2.136 亿美元的资金，以推进其生发口服药的商业化。根据文件中列出的发行后总股本计算，若按定价区间上限执行，Veradermics 的市值将达到约 5.34 亿美元。根据申报文件，Veradermics 在截至 9 月 30 日的九个月内净亏损为 4810 万美元，而去年同期的净亏损为 2080 万美元。Veradermics 的非激素脱发实验性治疗药物正处于临床后期试验阶段。此次 IPO 此前，Veradermics 曾于 10 月通过 C 轮融资筹集了 1.5 亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"“秃头经济”新玩家：生发药企Veradermics(MANE.US)拟IPO募资2.14亿美元，市值冲刺5.34亿","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veradermics.com","stockEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":-0.0663},{"period":"3month","weight":0.6142},{"period":"6month","weight":5.4418},{"period":"ytd","weight":5.4418}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"VeraDermics, Incorporated成立于2019年10月5日，最初位于德克萨斯州，后于2021年9月15日转换为特拉华州公司。这家由皮肤科医生创办的晚期临床阶段生物制药公司专注于开发针对普遍存在的美学和皮肤病状况的创新疗法。VeraDermics主要致力于解决影响美国众多个体的模式性脱发（PHL）治疗挑战。公司目前正在推进其主要候选药物VDPHL01，这是一种口服非激素治疗，旨在优化毛发生长，同时最小化与传统疗法相关的副作用。VeraDermics正在进行关键临床试验，以支持监管审批，并通过其针对性的治疗方法，旨在改变PHL的管理方式。","exchange":"NYSE","name":"Veradermics, Inc.","nameEN":"Veradermics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Veradermics, Inc.(MANE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Veradermics, Inc.(MANE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Veradermics, Inc.,MANE,Veradermics, Inc.股票,Veradermics, Inc.股票老虎,Veradermics, Inc.股票老虎国际,Veradermics, Inc.行情,Veradermics, Inc.股票行情,Veradermics, Inc.股价,Veradermics, Inc.股市,Veradermics, Inc.股票价格,Veradermics, Inc.股票交易,Veradermics, Inc.股票购买,Veradermics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Veradermics, Inc.(MANE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Veradermics, Inc.(MANE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}